Disease | tuberculosis |
Phenotype | C0021390|inflammatory bowel disease |
Sentences | 8 |
PubMedID- 25581784 | Objective: real-world epidemiological data on tuberculosis (tb) infection in patients with inflammatory bowel disease (ibd) receiving tnf-alpha inhibitors are scarce. |
PubMedID- 25349559 | Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. |
PubMedID- 20722065 | Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. |
PubMedID- 24378597 | Background: factors associated with performance of interferon-gamma release assays (igra) and the tuberculin skin test (tst) in screening for latent tuberculosis infection in patients with inflammatory bowel diseases (ibd) are still poorly understood. |
PubMedID- 25805938 | Aim: to evaluate the incidence and risk factors of korean tuberculosis (tb) infection in patients with inflammatory bowel disease (ibd) undergoing anti-tnf treatment. |
PubMedID- 26139305 | The impact of immunosuppressive therapy on quantiferon and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-tnf therapy. |
PubMedID- 22978645 | Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with tnf-alpha inhibitors. |
PubMedID- 25528041 | Clinical manifestations of gastrointestinal tuberculosis can lead to a misdiagnosed inflammatory bowel disease, advanced ovarian cancer, ileocecal cancer, mycosis, yersinia infection and amebomas [1]. |
Page: 1